VEGFA and breast cancer: Conversely, research utilizing a spontaneous breast cancer model characterized by high VEGF sensitivity revealed that treatment with FG-4497, a HIF-PHI drug of the same class as Roxadustat, did not enhance tumorigenesis or progression, even though VEGF levels were elevated (Seeley et al., 2017).